MIR513C: A Drug Target / Disease Biomarker (G100302114)

Target Name: MIR513C

NCBI ID: G100302114

MIR513C

MIR513C: A Drug Target / Disease Biomarker

MIR513C, a protein found in the immune system, has been identified as a potential drug target or biomarker for various diseases. Its unique structure and function make it an attractive target for researchers to study and develop new treatments.

MIR513C is a protein that is expressed in various tissues and cells of the body, including the immune system, skin, and heart. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. MIR513C is characterized by its unique structure, which consists of a long amino acid sequence and a characteristic domain that is involved in the interaction with other proteins.

One of the key features of MIR513C is its ability to interact with multiple proteins at once. This interaction is critical for its function in the immune system, where MIR513C plays a role in the regulation of T cell responses. MIR513C has been shown to interact with several key players in the immune system, including the cytoplasmic protein PDGF-R2 and the nuclear protein nuclear factor of activated T cells (NFAT).

MIR513C's unique structure and interaction with other proteins have also led to its potential as a drug target. Researchers are interested in using MIR513C as a target for new treatments for various diseases, including cancer, autoimmune diseases, and respiratory infections.

One of the reasons why MIR513C has generated so much interest is its location on the cell surface. MIR513C is a protein that is expressed in the cytoplasm, which is the fluid inside cells. This makes it an attractive target for drugs that can disrupt its function and disrupt the balance of proteins in the cytoplasm.

In addition, MIR513C's structure is also well- conserved, which is important for its stability and stability in the body. This makes it a good candidate for drugs that can modulate its function without disrupting its structure.

MIR513C has also been shown to play a role in several diseases, including cancer, autoimmune diseases, and respiratory infections. For example, studies have shown that MIR513C is overexpressed in several types of cancer, including breast, lung, and colon cancer. This suggests that MIR513C may be a useful target for new treatments for these diseases.

In addition, MIR513C has also been shown to play a role in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, and MIR513C has been shown to be involved in the regulation of the immune response.

MIR513C has also been shown to play a role in respiratory infections, such as pneumonia and asthma. These diseases are characterized by the immune system causing inflammation and damage to the lungs, and MIR513C has been shown to be involved in the regulation of the immune response in these diseases.

In conclusion, MIR513C is a protein that has the potential to be a drug target or biomarker for various diseases. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of MIR513C in the immune system and its potential as a drug target.

Protein Name: MicroRNA 513c

The "MIR513C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR513C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets